Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

A busy busi­ness de­vel­op­ment team at No­var­tis has made der­ma­tol­ogy the fo­cus of their lat­est bil­lion-dol­lar deal.

The cho­sen drug is MOR106, an IL-17C mon­o­clon­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER